Adial Pharmaceuticals, Inc. (ADIL)Â
NASDAQ$0.738
Market Cap
$4.85M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
424 of 922
Rank in Industry
251 of 526
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ADIL Insider Trading Activity
ADIL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Insider Activity of Adial Pharmaceuticals, Inc.
Over the last 12 months, insiders at Adial Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Adial Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Adial Pharmaceuticals, Inc. have bought $70,703 and sold $399,250 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 700 shares for transaction amount of $1,918 was made by Schuyler Kevin (director) on 2023‑09‑29.
List of Insider Buy and Sell Transactions, Adial Pharmaceuticals, Inc.
| 2023-09-29 | Schuyler Kevin | director | 700 0.0566% | $2.74 | $1,918 | -50.18% | ||
| 2021-12-30 | Newman James W. Jr. | director | 25,000 0.1356% | $2.69 | $67,300 | -53.00% | ||
| 2021-11-30 | Stilley William B. III | Chief Executive Officer | 10,600 0.0565% | $2.75 | $29,179 | -51.80% | ||
| 2021-11-29 | Stilley William B. III | Chief Executive Officer | 10,000 0.0544% | $2.59 | $25,892 | -47.27% | ||
| 2021-11-26 | Newman James W. Jr. | director | 10,000 0.0538% | $2.85 | $28,500 | -52.28% | ||
| 2021-04-06 | Sale | Johnson Bankole A. | Chief Medical Officer | 150,000 0.8494% | $2.50 | $375,000 | +4.38% | |
| 2020-08-20 | Sale | Johnson Bankole A. | Chief Medical Officer | 350,000 2.0553% | $1.21 | $423,500 | +47.02% | |
| 2020-03-27 | Newman James W. Jr. | director | 19,644 0.1848% | $1.36 | $26,769 | +23.91% | ||
| 2020-03-26 | Stilley William B. III | Chief Executive Officer | 12,652 0.1363% | $1.47 | $18,598 | +31.54% | ||
| 2020-03-25 | Stilley William B. III | Chief Executive Officer | 12,348 0.1072% | $1.13 | $13,953 | +37.90% | ||
| 2019-12-12 | Sale | Johnson Bankole A. | Chief Medical Officer | 150,000 0.8506% | $1.00 | $150,000 | -7.44% | |
| 2019-03-29 | Johnson Bankole A. | Chief Medical Officer | 33,100 0.4057% | $3.47 | $114,801 | -50.44% | ||
| 2019-03-28 | Johnson Bankole A. | Chief Medical Officer | 40,000 0.4706% | $3.15 | $125,808 | -47.53% | ||
| 2018-07-31 | Stilley William B. III | Chief Executive Officer | 80,000 1.8029% | $5.00 | $400,000 | -28.75% | ||
| 2018-07-31 | Schuyler Kevin | director | 180,000 2.0282% | $2.50 | $450,000 | -28.75% | ||
| 2018-07-31 | Newman James W. Jr. | director | 20,000 0.4507% | $5.00 | $100,000 | -28.75% | ||
| 2018-07-31 | Gilliland Robertson H. | director | 14,000 0.3155% | $5.00 | $70,000 | -28.75% | ||
| 2018-07-31 | Goodman Tony | director | 14,000 0.3549% | $5.63 | $78,750 | -28.75% | ||
| 2018-07-31 | Johnson Bankole A. | 1,400 0.0316% | $5.00 | $7,000 | -28.75% |
Total: 19
Insider Historical Profitability
<0.0001%
| Stilley William B. III | Chief Executive Officer | 937646 14.2617% | $691,982.75 | 5 | 0 | <0.0001% |
| Johnson Bankole A. | Chief Medical Officer | 548336 8.3402% | $404,671.97 | 3 | 3 | <0.0001% |
| Gilliland Robertson H. | director | 109424 1.6643% | $80,754.91 | 1 | 0 | <0.0001% |
| Newman James W. Jr. | director | 50221 0.7639% | $37,063.10 | 4 | 0 | <0.0001% |
| Goodman Tony | director | 8755 0.1332% | $6,461.19 | 1 | 0 | <0.0001% |
| Schuyler Kevin | director | 700 0.0106% | $516.60 | 2 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $6.66M | |
$31,129 | 22 | -11.96% | $6.23M | |
$1,616,354 | 20 | -12.22% | $3.49M | |
$51,865 | 17 | -38.70% | $6.16M | |
$960,082 | 17 | -6.29% | $5.58M | |
Adial Pharmaceuticals, Inc. (ADIL) | $1,558,469 | 16 | -26.98% | $4.85M |
$111,212 | 12 | -28.79% | $3.41M | |
$309,830 | 10 | -55.78% | $4.23M | |
$111,748 | 9 | -47.72% | $3.59M | |
$713,979 | 6 | -14.06% | $5.27M | |
$726,438 | 4 | -72.85% | $4.85M | |
$76,299 | 4 | 11.60% | $6.34M | |
$105,480 | 3 | -97.42% | $4.94M | |
$1,057,000 | 3 | 5.27% | $3.86M | |
$14,530 | 3 | 62.23% | $6M | |
$608,453 | 3 | -53.52% | $3.6M | |
$165,600 | 2 | -3.58% | $3.51M | |
$4,423 | 2 | 3.27% | $6.69M | |
$739,010 | 1 | 3.33% | $3.83M |
ADIL Institutional Investors: Active Positions
| Increased Positions | 7 | +58.33% | 129,943 | +66.95% |
| Decreased Positions | 3 | -25% | 30,720 | -15.83% |
| New Positions | 4 | New | 75,710 | New |
| Sold Out Positions | <1 | Sold Out | 27,115 | Sold Out |
| Total Postitions | 16 | +33.33% | 293,316 | +51.12% |
ADIL Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Geode Capital Management, Llc | $43.00 | 0.88% | 61,847 | +16,381 | +36.03% | 2024-12-31 |
| Citadel Advisors Llc | $38.00 | 0.78% | 54,508 | +21,238 | +63.84% | 2024-12-31 |
| Manchester Capital Management Llc | $33.00 | 0.69% | 48,097 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $33.00 | 0.68% | 47,613 | +47,613 | New | 2024-12-31 |
| Blackrock, Inc. | $19.00 | 0.4% | 27,770 | 0 | 0% | 2024-12-31 |
| Cambridge Investment Research Advisors, Inc. | $19.00 | 0.39% | 27,000 | +27,000 | New | 2024-12-31 |
| Ubs Group Ag | $15.00 | 0.3% | 21,018 | +16,614 | +377.25% | 2024-12-31 |
| 1620 Investment Advisors, Inc. | $2.00 | 0.05% | 3,600 | 0 | 0% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $1.00 | 0.01% | 937 | +937 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $0 | 0.01% | 638 | -3,305 | -83.82% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.